{"links":{"self":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news","first":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news?page=1","next":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news?page=2","prev":null,"last":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news?page=3"},"meta":{"executionDate":"2024-09-25T18:18:09","cmsDomain":"http://axsometherapeuticsinc.gcs-web.com","count":100},"data":[{"id":11671,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11671","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-presents-data-multiple-programs-sleep-europe"},"title":"Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024","type":{"title":"General","id":3886},"teaser":"Seven presentations highlight the Company’s growing CNS portfolio and commitment to improving treatment outcomes for patients with sleep disorders NEW YORK , Sept. 24, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel","language":"en","releaseDate":{"dateUTC":"2024-09-24T11:00:00","date":"2024-09-24T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11671/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-09-24T11:00:45","lastUpdatedUTC":"2024-09-24T11:00:45"},{"id":11641,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11641","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-fda-acceptance-nda-resubmission"},"title":"Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine","type":{"title":"General","id":3886},"teaser":"FDA sets PDUFA action goal date of January 31, 2025 NEW YORK , Sept. 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that the","language":"en","releaseDate":{"dateUTC":"2024-09-04T11:00:00","date":"2024-09-04T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11641/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-09-04T11:00:36","lastUpdatedUTC":"2024-09-04T11:00:36"},{"id":11636,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11636","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-participate-investor-conferences-september"},"title":"Axsome Therapeutics to Participate in Investor Conferences in September","type":{"title":"General","id":3886},"teaser":"Morgan Stanley 22 nd Annual Global Healthcare Conference on September 4 in New York Wells Fargo Healthcare Conference on September 5 in Boston Baird 2024 Global Healthcare Conference on September 11 in New York Cantor Global Healthcare Conference on September 18 in New York NEW YORK , Aug.","language":"en","releaseDate":{"dateUTC":"2024-08-27T11:00:00","date":"2024-08-27T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Participate in Investor Conferences in September","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11636/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-08-27T11:00:30","lastUpdatedUTC":"2024-08-27T11:00:30"},{"id":11616,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11616","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-reaches-agreement-dismiss-sunosir"},"title":"Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.","type":{"title":"General","id":3886},"teaser":"NEW YORK , Aug. 21, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, today announced that it has reached agreement with Sandoz Inc.","language":"en","releaseDate":{"dateUTC":"2024-08-21T11:00:00","date":"2024-08-21T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11616/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-08-21T11:01:04","lastUpdatedUTC":"2024-08-21T11:01:04"},{"id":11586,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11586","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-reports-second-quarter-2024-financial"},"title":"Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update","type":{"title":"Earnings","id":3896},"teaser":"Total 2Q 2024 net product revenue of $87.2 million , representing 87% year-over-year growth Auvelity® 2Q 2024 net product sales of $65.0 million , representing 135% year-over-year growth Sunosi® 2Q 2024 net product revenue of $22.1 million representing 16% year-over-year growth NDA for AXS-07 in","language":"en","releaseDate":{"dateUTC":"2024-08-05T11:00:00","date":"2024-08-05T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11586/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-08-05T11:00:36","lastUpdatedUTC":"2024-08-05T11:00:36"},{"id":11571,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11571","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-report-second-quarter-2024-financial-results"},"title":"Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5","type":{"title":"General","id":3886},"teaser":"NEW YORK , July 11, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of","language":"en","releaseDate":{"dateUTC":"2024-07-11T11:00:00","date":"2024-07-11T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11571/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-07-11T11:02:27","lastUpdatedUTC":"2024-07-11T11:02:27"},{"id":11531,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11531","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-settles-sunosir-solriamfetol-patent"},"title":"Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories","type":{"title":"General","id":3886},"teaser":"NEW YORK , June 05, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, today announced that it has entered into a settlement agreement with Unichem","language":"en","releaseDate":{"dateUTC":"2024-06-05T11:35:00","date":"2024-06-05T07:35:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11531/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-06-05T11:35:18","lastUpdatedUTC":"2024-06-05T11:35:18"},{"id":11526,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11526","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-joins-american-migraine-foundation-highlight"},"title":"Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month","type":{"title":"General","id":3886},"teaser":"NEW YORK , June 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced today it is joining the migraine advocacy community to raise awareness","language":"en","releaseDate":{"dateUTC":"2024-06-04T11:00:00","date":"2024-06-04T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11526/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-06-04T11:00:38","lastUpdatedUTC":"2024-06-04T11:00:38"},{"id":11521,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11521","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-supports-alzheimers-brain-awareness-month"},"title":"Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month","type":{"title":"General","id":3886},"teaser":"NEW YORK , June 03, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced today it is supporting Alzheimer’s & Brain Awareness Month this June,","language":"en","releaseDate":{"dateUTC":"2024-06-03T11:00:00","date":"2024-06-03T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11521/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-06-03T11:00:37","lastUpdatedUTC":"2024-06-03T11:00:37"},{"id":11511,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11511","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-participate-upcoming-investor-conferences"},"title":"Axsome Therapeutics to Participate in Upcoming Investor Conferences","type":{"title":"General","id":3886},"teaser":"NEW YORK , May 30, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Axsome will participate in two upcoming investor","language":"en","releaseDate":{"dateUTC":"2024-05-30T11:00:00","date":"2024-05-30T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Participate in Upcoming Investor Conferences","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11511/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-05-30T11:00:43","lastUpdatedUTC":"2024-05-30T11:00:43"},{"id":11486,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11486","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-highlights-data-solriamfetol-demonstrating"},"title":"Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024","type":{"title":"General","id":3886},"teaser":"Data on solriamfetol featured in two oral plenary sessions NEW YORK , May 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced five","language":"en","releaseDate":{"dateUTC":"2024-05-29T11:00:00","date":"2024-05-29T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11486/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-05-29T11:00:44","lastUpdatedUTC":"2024-05-29T11:00:44"},{"id":11476,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11476","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-presents-data-multiple-programs-2024"},"title":"Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting","type":{"title":"General","id":3886},"teaser":"NEW YORK , May 28, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that data from its industry-leading portfolio of novel products","language":"en","releaseDate":{"dateUTC":"2024-05-28T11:00:00","date":"2024-05-28T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11476/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-05-28T11:00:35","lastUpdatedUTC":"2024-05-28T11:00:35"},{"id":11461,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11461","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-present-upcoming-investor-conferences-8"},"title":"Axsome Therapeutics to Present at Upcoming Investor Conferences","type":{"title":"General","id":3886},"teaser":"NEW YORK , May 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau , MD, Axsome’s Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2024-05-08T11:00:00","date":"2024-05-08T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Present at Upcoming Investor Conferences","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11461/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-05-08T11:01:40","lastUpdatedUTC":"2024-05-08T11:01:40"},{"id":11446,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11446","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-reports-first-quarter-2024-financial-results"},"title":"Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update","type":{"title":"Earnings","id":3896},"teaser":"Total 1Q 2024 net product revenue of $75.0 million , representing 160% year-over-year growth Auvelity® 1Q 2024 net product sales of $53.4 million , representing 240% year-over-year growth Sunosi® 1Q 2024 net product revenue of $21.6 million representing 64% year-over-year growth Contract executed","language":"en","releaseDate":{"dateUTC":"2024-05-06T11:00:00","date":"2024-05-06T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11446/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-05-06T11:00:33","lastUpdatedUTC":"2024-05-06T11:00:33"},{"id":11441,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11441","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-recognizes-may-mental-health-awareness-month"},"title":"Axsome Therapeutics Recognizes May as Mental Health Awareness Month","type":{"title":"General","id":3886},"teaser":"NEW YORK , May 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today is joining the global community of mental health advocates, including","language":"en","releaseDate":{"dateUTC":"2024-05-01T11:00:00","date":"2024-05-01T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Recognizes May as Mental Health Awareness Month","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11441/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-05-01T11:00:33","lastUpdatedUTC":"2024-05-01T11:00:33"},{"id":11421,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11421","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-highlights-innovative-neuroscience-portfolio"},"title":"Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting","type":{"title":"General","id":3886},"teaser":"AXS-05 in Alzheimer’s disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in pooled analysis Presentations on cognitive and wake promoting effects of solriamfetol NEW YORK , April 15, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc.","language":"en","releaseDate":{"dateUTC":"2024-04-15T11:00:00","date":"2024-04-15T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11421/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-04-15T11:00:30","lastUpdatedUTC":"2024-04-15T11:00:30"},{"id":11411,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11411","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-report-first-quarter-2024-financial-results"},"title":"Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6","type":{"title":"General","id":3886},"teaser":"NEW YORK , April 10, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it will report its financial results for the first quarter of","language":"en","releaseDate":{"dateUTC":"2024-04-10T11:00:00","date":"2024-04-10T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11411/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-04-10T11:00:26","lastUpdatedUTC":"2024-04-10T11:00:26"},{"id":11386,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11386","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-initiates-engage-phase-3-trial-solriamfetol"},"title":"Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder","type":{"title":"General","id":3886},"teaser":"NEW YORK , April 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced the initiation of the ENGAGE Phase 3 trial of solriamfetol, an","language":"en","releaseDate":{"dateUTC":"2024-04-01T11:00:00","date":"2024-04-01T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11386/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-04-01T11:00:43","lastUpdatedUTC":"2024-04-01T11:00:43"},{"id":11366,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11366","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-results-crescendo-narcolepsy"},"title":"Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients","type":{"title":"Earnings","id":3896},"teaser":"77% of narcolepsy type 1 patients continue to experience cataplexy attacks despite being treated 64% of narcolepsy type 1 patients continue to experience excessive daytime sleepiness, as assessed by the Epworth Sleepiness Scale (ESS), despite being treated 74% of treated narcolepsy type 1 patients","language":"en","releaseDate":{"dateUTC":"2024-03-25T11:00:00","date":"2024-03-25T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11366/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-03-25T11:00:24","lastUpdatedUTC":"2024-03-25T11:00:24"},{"id":11361,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11361","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-axs-12-achieves-primary-endpoint-0"},"title":"Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy","type":{"title":"General","id":3886},"teaser":"AXS-12 statistically significantly reduced cataplexy attacks compared to placebo (p=0.018, primary endpoint) AXS-12 achieved statistically significant remission of cataplexy compared to placebo (p=0.008) AXS-12 statistically significantly reduced excessive daytime sleepiness (EDS) severity compared","language":"en","releaseDate":{"dateUTC":"2024-03-25T10:30:00","date":"2024-03-25T06:30:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11361/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-03-25T10:30:26","lastUpdatedUTC":"2024-03-25T10:30:26"},{"id":11346,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11346","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-initiates-paradigm-phase-3-trial"},"title":"Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder","type":{"title":"General","id":3886},"teaser":"NEW YORK , March 19, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the first patient has been dosed in the PARADIGM Phase 3 trial","language":"en","releaseDate":{"dateUTC":"2024-03-19T11:00:00","date":"2024-03-19T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11346/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-03-19T11:00:34","lastUpdatedUTC":"2024-03-19T11:00:34"},{"id":11321,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11321","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-present-leerink-partners-global-biopharma"},"title":"Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference","type":{"title":"General","id":3886},"teaser":"NEW YORK , March 05, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau , MD, Axsome’s Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2024-03-05T12:00:00","date":"2024-03-05T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11321/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-03-05T12:00:29","lastUpdatedUTC":"2024-03-05T12:00:29"},{"id":11271,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11271","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-present-td-cowen-44th-annual-healthcare"},"title":"Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference","type":{"title":"General","id":3886},"teaser":"NEW YORK , Feb. 27, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau , MD, Axsome’s Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2024-02-27T12:00:00","date":"2024-02-27T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11271/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-02-27T12:00:37","lastUpdatedUTC":"2024-02-27T12:00:37"},{"id":11251,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11251","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-reports-fourth-quarter-and-full-year-2023"},"title":"Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update","type":{"title":"Earnings","id":3896},"teaser":"Total 4Q and full year 2023 net product revenue of $71.5 million and $204.9 million , respectively, representing year-over-year growth of 193% and 309% Auvelity 4Q and full year 2023 net product sales of $49.0 million and $130.1 million , respectively, during the first full year of launch Sunosi 4Q","language":"en","releaseDate":{"dateUTC":"2024-02-20T12:00:00","date":"2024-02-20T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11251/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-02-20T12:01:10","lastUpdatedUTC":"2024-02-20T12:01:10"},{"id":11211,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11211","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-report-fourth-quarter-and-full-year-2023"},"title":"Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20","type":{"title":"General","id":3886},"teaser":"NEW YORK , Jan. 23, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it will report its financial results for the fourth quarter and","language":"en","releaseDate":{"dateUTC":"2024-01-23T12:00:00","date":"2024-01-23T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11211/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-01-23T12:00:17","lastUpdatedUTC":"2024-01-23T12:00:17"},{"id":11191,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11191","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-provides-preliminary-fourth-quarter-and-full"},"title":"Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones","type":{"title":"General","id":3886},"teaser":"Preliminary total 4Q and full year 2023 net product revenue of $71 million and $204 million , respectively Auvelity preliminary 4Q and full year 2023 net product sales of $49 million and $130 million , respectively Sunosi preliminary 4Q and full year 2023 net product revenue of $22 million and $74","language":"en","releaseDate":{"dateUTC":"2024-01-04T12:00:00","date":"2024-01-04T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11191/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-01-04T12:00:32","lastUpdatedUTC":"2024-01-04T12:00:32"},{"id":11181,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11181","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-presents-new-data-and-post-hoc-analyses"},"title":"Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting","type":{"title":"General","id":3886},"teaser":"New data on Auvelity’s impact on quality of life, measured by the Q-LES-Q-SF, in patients who had received at least one prior treatment during their current depressive episode Data on Auvelity exploring reduction of depressive symptoms regardless of a patient’s interest-activity symptom severity","language":"en","releaseDate":{"dateUTC":"2023-12-11T12:00:00","date":"2023-12-11T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11181/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-12-11T12:00:49","lastUpdatedUTC":"2023-12-11T12:00:49"},{"id":11166,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11166","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-hosts-solriamfetol-virtual-investor-event"},"title":"Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today","type":{"title":"General","id":3886},"teaser":"NEW YORK , Dec. 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, is hosting a virtual investor event and conference call today from 8 a.m.","language":"en","releaseDate":{"dateUTC":"2023-12-07T12:00:00","date":"2023-12-07T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11166/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-12-07T12:00:45","lastUpdatedUTC":"2023-12-07T12:00:45"},{"id":11161,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11161","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-host-solriamfetol-virtual-investor-event"},"title":"Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7","type":{"title":"General","id":3886},"teaser":"NEW YORK , Nov. 22, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will host a virtual event on December 7 from 8 a.m.","language":"en","releaseDate":{"dateUTC":"2023-11-22T12:00:00","date":"2023-11-22T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11161/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-11-22T12:00:34","lastUpdatedUTC":"2023-11-22T12:00:34"},{"id":11151,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11151","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-present-piper-sandler-35th-annual-healthcare"},"title":"Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference","type":{"title":"General","id":3886},"teaser":"NEW YORK , Nov. 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau , MD, Axsome’s Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2023-11-21T12:00:00","date":"2023-11-21T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11151/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-11-21T12:00:59","lastUpdatedUTC":"2023-11-21T12:00:59"},{"id":11126,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11126","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-reports-third-quarter-2023-financial-results"},"title":"Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update","type":{"title":"Earnings","id":3896},"teaser":"Total 3Q 2023 product revenue of $57.8 million , representing 244% year-over-year growth Auvelity ® 3Q 2023 net product sales of $37.7 million , representing 36% quarter-over-quarter growth Sunosi ® 3Q 2023 net product revenue of $20.1 million , representing 20% year-over-year growth SYMPHONY Phase","language":"en","releaseDate":{"dateUTC":"2023-11-06T12:00:00","date":"2023-11-06T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11126/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-11-06T12:00:46","lastUpdatedUTC":"2023-11-06T12:00:46"},{"id":11121,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11121","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-and-global-alzheimers-disease-community-come"},"title":"Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023","type":{"title":"General","id":3886},"teaser":"Axsome’s headquarters to be lit in teal as part of the Alzheimer’s Foundation of America awareness campaign NEW YORK , Nov. 02, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central","language":"en","releaseDate":{"dateUTC":"2023-11-02T11:00:00","date":"2023-11-02T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11121/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-11-02T11:00:54","lastUpdatedUTC":"2023-11-02T11:00:54"},{"id":11116,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11116","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-present-upcoming-investor-conferences-7"},"title":"Axsome Therapeutics to Present at Upcoming Investor Conferences","type":{"title":"General","id":3886},"teaser":"NEW YORK , Oct. 31, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau , MD, Axsome’s Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2023-10-31T11:00:00","date":"2023-10-31T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Present at Upcoming Investor Conferences","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11116/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-10-31T11:00:57","lastUpdatedUTC":"2023-10-31T11:00:57"},{"id":11111,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11111","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-presents-results-accord-trial-axs-05"},"title":"Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference","type":{"title":"General","id":3886},"teaser":"NEW YORK , Oct. 24, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced a presentation of data from its ACCORD Phase 3 clinical trial of","language":"en","releaseDate":{"dateUTC":"2023-10-24T11:00:00","date":"2023-10-24T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11111/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-10-24T11:00:45","lastUpdatedUTC":"2023-10-24T11:00:45"},{"id":11091,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11091","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-appoints-dr-sue-mahony-its-board-directors"},"title":"Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors","type":{"title":"General","id":3886},"teaser":"NEW YORK , Oct. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Susan Mahony , PhD, has been appointed to Axsome’s board of","language":"en","releaseDate":{"dateUTC":"2023-10-11T11:00:00","date":"2023-10-11T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11091/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-10-11T11:00:36","lastUpdatedUTC":"2023-10-11T11:00:36"},{"id":11081,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11081","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-report-third-quarter-2023-financial-results"},"title":"Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6","type":{"title":"General","id":3886},"teaser":"Axsome to host conference call and webcast on Monday, Nov. 6, 2023, at 8:00 a.m. Eastern Time NEW YORK , Oct. 10, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system","language":"en","releaseDate":{"dateUTC":"2023-10-10T11:00:00","date":"2023-10-10T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11081/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-10-10T11:00:37","lastUpdatedUTC":"2023-10-10T11:00:37"},{"id":11076,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11076","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-joins-national-alliance-mental-illness-and"},"title":"Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week","type":{"title":"General","id":3886},"teaser":"NEW YORK , Oct. 02, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it is joining patient advocacy organizations, including the","language":"en","releaseDate":{"dateUTC":"2023-10-02T11:00:00","date":"2023-10-02T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11076/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-10-02T11:00:39","lastUpdatedUTC":"2023-10-02T11:00:39"},{"id":11071,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11071","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-joins-global-narcolepsy-community-raising"},"title":"Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day","type":{"title":"General","id":3886},"teaser":"NEW YORK , Sept. 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it is joining the global narcolepsy advocacy community,","language":"en","releaseDate":{"dateUTC":"2023-09-21T11:00:00","date":"2023-09-21T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11071/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-09-21T11:00:30","lastUpdatedUTC":"2023-09-21T11:00:30"},{"id":11056,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11056","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-highlights-commitment-innovating-treatments"},"title":"Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023","type":{"title":"General","id":3886},"teaser":"Data presentations explore effects on patient-centric efficacy measures of treatments for patients with depression, and excessive sleepiness associated with obstructive sleep apnea and narcolepsy NEW YORK , Sept. 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc.","language":"en","releaseDate":{"dateUTC":"2023-09-07T11:03:00","date":"2023-09-07T07:03:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11056/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-09-07T11:03:36","lastUpdatedUTC":"2023-09-07T11:03:36"},{"id":11051,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11051","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-present-three-upcoming-investor-conferences"},"title":"Axsome Therapeutics to Present at Three Upcoming Investor Conferences","type":{"title":"General","id":3886},"teaser":"NEW YORK , Sept. 05, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau , MD, Axsome’s Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2023-09-05T11:00:00","date":"2023-09-05T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Present at Three Upcoming Investor Conferences","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11051/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-09-05T11:00:29","lastUpdatedUTC":"2023-09-05T11:00:29"},{"id":11011,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11011","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-reports-second-quarter-2023-financial"},"title":"Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update","type":{"title":"Earnings","id":3896},"teaser":"Total 2Q 2023 product revenue of $46.7 million Auvelity ® 2Q 2023 net product sales of $27.6 million , representing 76% quarter-over-quarter growth Sunosi ® 2Q 2023 net product revenue of $19.1 million Pro forma second quarter cash balance of $468.8 million FOCUS Phase 3 trial of solriamfetol in","language":"en","releaseDate":{"dateUTC":"2023-08-07T11:00:00","date":"2023-08-07T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/11011/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-08-07T11:00:29","lastUpdatedUTC":"2023-08-07T11:00:29"},{"id":10996,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10996","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-report-second-quarter-2023-financial-results"},"title":"Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7","type":{"title":"General","id":3886},"teaser":"Axsome to host conference call and webcast on Monday, Aug. 7, 2023, at 8:00 a.m. Eastern Time NEW YORK , July 12, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system","language":"en","releaseDate":{"dateUTC":"2023-07-12T11:00:00","date":"2023-07-12T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10996/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-07-12T11:00:22","lastUpdatedUTC":"2023-07-12T11:00:22"},{"id":10981,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10981","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-initiates-focus-phase-3-trial-solriamfetol"},"title":"Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults","type":{"title":"General","id":3886},"teaser":"NEW YORK , July 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it has dosed the first patient in the FOCUS Phase 3 trial","language":"en","releaseDate":{"dateUTC":"2023-07-07T11:00:00","date":"2023-07-07T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10981/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-07-07T11:01:22","lastUpdatedUTC":"2023-07-07T11:01:22"},{"id":10971,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10971","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-closing-public-offering-225"},"title":"Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock","type":{"title":"General","id":3886},"teaser":"NEW YORK , June 30, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the closing of its previously","language":"en","releaseDate":{"dateUTC":"2023-06-30T20:02:00","date":"2023-06-30T16:02:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10971/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-06-30T20:04:56","lastUpdatedUTC":"2023-06-30T20:04:56"},{"id":10956,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10956","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-pricing-public-offering-225"},"title":"Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock","type":{"title":"General","id":3886},"teaser":"NEW YORK , June 28, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the pricing of an underwritten","language":"en","releaseDate":{"dateUTC":"2023-06-28T13:28:00","date":"2023-06-28T09:28:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10956/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-06-28T13:28:41","lastUpdatedUTC":"2023-06-28T13:28:41"},{"id":10946,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10946","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-proposed-public-offering-common-1"},"title":"Axsome Therapeutics Announces Proposed Public Offering of Common Stock","type":{"title":"General","id":3886},"teaser":"NEW YORK , June 27, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it intends to offer and sell shares of its","language":"en","releaseDate":{"dateUTC":"2023-06-28T00:24:00","date":"2023-06-27T20:24:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Announces Proposed Public Offering of Common Stock","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10946/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-06-28T00:24:58","lastUpdatedUTC":"2023-06-28T00:24:58"},{"id":10906,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10906","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-present-new-sunosir-data-sleep-2023"},"title":"Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023","type":{"title":"General","id":3886},"teaser":"Cognitive improvement with Sunosi sustained over eight hours in patients with excessive daytime sleepiness due to obstructive sleep apnea NEW YORK , June 01, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for","language":"en","releaseDate":{"dateUTC":"2023-06-01T11:00:00","date":"2023-06-01T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10906/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-06-01T11:00:50","lastUpdatedUTC":"2023-06-01T11:00:50"},{"id":10901,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10901","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-present-data-and-post-hoc-analyses-auvelityr"},"title":"Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting","type":{"title":"General","id":3886},"teaser":"Data on Auvelity demonstrating improved functioning in major depressive disorder Data on Sunosi demonstrating improved cognitive function in patients with excessive daytime sleepiness associated with obstructive sleep apnea NEW YORK , May 30, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc.","language":"en","releaseDate":{"dateUTC":"2023-05-30T11:00:00","date":"2023-05-30T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10901/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-05-30T11:01:24","lastUpdatedUTC":"2023-05-30T11:01:24"},{"id":10881,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10881","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-reports-first-quarter-2023-financial-results"},"title":"Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update","type":{"title":"Earnings","id":3896},"teaser":"Auvelity ® 1Q 2023 net product sales of $15.7 million Total 1Q 2023 net product sales of $28.6 million Total 1Q 2023 revenue of $94.6 million , including Sunosi ® ex- U.S. license agreement upfront payment Company to host conference call today at 8:00 AM Eastern NEW YORK , May 08, 2023 (GLOBE","language":"en","releaseDate":{"dateUTC":"2023-05-08T11:00:00","date":"2023-05-08T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10881/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-05-08T11:00:31","lastUpdatedUTC":"2023-05-08T11:00:31"},{"id":10871,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10871","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-present-bank-america-securities-2023"},"title":"Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference","type":{"title":"General","id":3886},"teaser":"NEW YORK , May 03, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau , MD, Axsome’s Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2023-05-03T11:00:00","date":"2023-05-03T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10871/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-05-03T11:01:14","lastUpdatedUTC":"2023-05-03T11:01:14"},{"id":10866,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10866","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-joins-mental-health-america-and-state-new"},"title":"Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month","type":{"title":"General","id":3886},"teaser":"One World Trade Center to be lit up in green in observance of Mental Health Month NEW YORK , May 01, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders,","language":"en","releaseDate":{"dateUTC":"2023-05-01T11:00:00","date":"2023-05-01T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10866/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-05-01T11:00:53","lastUpdatedUTC":"2023-05-01T11:00:53"},{"id":10851,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10851","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-present-five-abstracts-including-new-data"},"title":"Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting","type":{"title":"General","id":3886},"teaser":"NEW YORK , April 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will be presenting five abstracts at the upcoming 2023","language":"en","releaseDate":{"dateUTC":"2023-04-21T11:00:00","date":"2023-04-21T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10851/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-04-21T11:00:53","lastUpdatedUTC":"2023-04-21T13:54:55"},{"id":10846,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10846","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-present-22nd-annual-needham-virtual"},"title":"Axsome Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference","type":{"title":"General","id":3886},"teaser":"NEW YORK , April 14, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau , MD, Axsome’s Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2023-04-14T11:00:00","date":"2023-04-14T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10846/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-04-14T11:01:05","lastUpdatedUTC":"2023-04-14T11:01:05"},{"id":10831,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10831","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-report-first-quarter-2023-financial-results"},"title":"Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8","type":{"title":"General","id":3886},"teaser":"Axsome to host conference call and webcast on Monday, May 8, 2023, at 8:00 a.m. Eastern Time NEW YORK , April 13, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system","language":"en","releaseDate":{"dateUTC":"2023-04-13T11:00:00","date":"2023-04-13T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10831/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-04-13T11:01:36","lastUpdatedUTC":"2023-04-13T11:01:36"},{"id":10771,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10771","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-present-cowens-43rd-annual-health-care"},"title":"Axsome Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference","type":{"title":"General","id":3886},"teaser":"NEW YORK , March 01, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau , MD, Axsome’s Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2023-03-01T12:00:00","date":"2023-03-01T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10771/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-03-01T12:00:43","lastUpdatedUTC":"2023-03-01T12:00:43"},{"id":10751,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10751","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-reports-fourth-quarter-and-full-year-2022"},"title":"Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update","type":{"title":"Earnings","id":3896},"teaser":"Total fourth quarter net product sales of $24.4 million Auvelity ® launched October 19th , with fourth quarter net product sales of $5.2 million Sunosi ® fourth quarter net product sales of $19.2 million Sunosi ® license agreement for EU announced – $66 million upfront, potential milestones up to","language":"en","releaseDate":{"dateUTC":"2023-02-27T12:00:00","date":"2023-02-27T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10751/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-02-27T12:00:34","lastUpdatedUTC":"2023-02-27T12:00:34"},{"id":10741,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10741","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-enters-license-agreement-pharmanovia-expand"},"title":"Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe","type":{"title":"General","id":3886},"teaser":"Axsome to receive an upfront payment of $66 million , and is eligible to receive sales-based and other milestones totaling up to $101 million Pharmanovia is responsible for all ongoing and future clinical studies in Europe and MENA NEW YORK , Feb. 22, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics,","language":"en","releaseDate":{"dateUTC":"2023-02-22T12:00:00","date":"2023-02-22T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10741/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-02-22T12:00:56","lastUpdatedUTC":"2023-02-22T12:00:56"},{"id":10701,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10701","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-present-svb-securities-global-biopharma"},"title":"Axsome Therapeutics to Present at the SVB Securities Global Biopharma Conference","type":{"title":"General","id":3886},"teaser":"NEW YORK , Feb. 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau , MD, Axsome’s Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2023-02-07T12:00:00","date":"2023-02-07T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Present at the SVB Securities Global Biopharma Conference","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10701/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-02-07T12:02:21","lastUpdatedUTC":"2023-02-07T12:02:21"},{"id":10686,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10686","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-report-fourth-quarter-and-full-year-2022"},"title":"Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27","type":{"title":"General","id":3886},"teaser":"Axsome to host conference call and webcast on Monday, Feb. 27, 2023, at 8:00 a.m. ET NEW YORK , Jan. 31, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS)","language":"en","releaseDate":{"dateUTC":"2023-01-31T12:00:00","date":"2023-01-31T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10686/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-01-31T12:00:44","lastUpdatedUTC":"2023-01-31T12:00:44"},{"id":10671,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10671","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-presents-new-data-evolve-open-label-trial"},"title":"Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annua","type":{"title":"General","id":3886},"teaser":"Improvement in cognitive and physical functioning, measured by the CPFQ patient-rated scale, starting at week 1 and sustained over 12 months Improvement in disability, measured by the SDS, starting at week 1 and sustained over 12 months NEW YORK , Dec.","language":"en","releaseDate":{"dateUTC":"2022-12-07T12:00:00","date":"2022-12-07T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annua","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10671/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-12-07T12:00:31","lastUpdatedUTC":"2022-12-07T12:00:31"},{"id":10651,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10651","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-axs-05-achieves-primary-endpoint-3"},"title":"Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation","type":{"title":"General","id":3886},"teaser":"AXS-05 statistically significantly delayed time to relapse of Alzheimer’s disease agitation versus placebo (p=0.014, primary endpoint) AXS-05 statistically significantly prevented relapse of Alzheimer’s disease agitation versus placebo (p=0.018, key secondary endpoint) Statistically significant","language":"en","releaseDate":{"dateUTC":"2022-11-28T11:35:00","date":"2022-11-28T06:35:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10651/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-11-28T11:35:12","lastUpdatedUTC":"2022-11-28T11:35:12"},{"id":10646,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10646","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-present-5th-annual-evercore-isi-healthconx"},"title":"Axsome Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference","type":{"title":"General","id":3886},"teaser":"NEW YORK , Nov. 23, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau , MD, Axsome’s Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2022-11-23T12:00:00","date":"2022-11-23T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10646/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-11-23T12:00:21","lastUpdatedUTC":"2022-11-23T12:00:21"},{"id":10631,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10631","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-present-guggenheim-4th-annual-immunology-and"},"title":"Axsome Therapeutics to Present at the Guggenheim 4th Annual Immunology and Neurology Conference","type":{"title":"General","id":3886},"teaser":"NEW YORK , Nov. 09, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau , MD, Axsome’s Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2022-11-09T12:00:00","date":"2022-11-09T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Present at the Guggenheim 4th Annual Immunology and Neurology Conference","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10631/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-11-09T12:00:27","lastUpdatedUTC":"2022-11-09T12:00:27"},{"id":10616,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10616","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-reports-third-quarter-2022-financial-results"},"title":"Axsome Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update","type":{"title":"Earnings","id":3896},"teaser":"Sunosi® third quarter U.S. net sales of $16.8 million Auvelity™ launched and available in U.S. pharmacies SHARP study results announced demonstrating statistically significant improvement in cognitive function with Sunosi versus placebo ADVANCE-2 trial of AXS-05 in Alzheimer’s disease agitation","language":"en","releaseDate":{"dateUTC":"2022-11-07T12:00:00","date":"2022-11-07T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10616/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-11-07T12:00:50","lastUpdatedUTC":"2022-11-07T12:00:50"},{"id":10611,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10611","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-ring-nasdaq-stock-market-opening-bell-today"},"title":"Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today","type":{"title":"General","id":3886},"teaser":"NEW YORK , Oct. 27, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau , MD, Axsome’s Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2022-10-27T11:00:00","date":"2022-10-27T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10611/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-10-27T11:00:52","lastUpdatedUTC":"2022-10-27T11:00:52"},{"id":10591,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10591","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-report-third-quarter-2022-financial-results"},"title":"Axsome Therapeutics to Report Third Quarter 2022 Financial Results on November 7, 2022","type":{"title":"General","id":3886},"teaser":"Axsome to host conference call and webcast on Monday, November 7, 2022 at 8:00 AM Eastern Time NEW YORK , Oct. 21, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system","language":"en","releaseDate":{"dateUTC":"2022-10-21T11:00:00","date":"2022-10-21T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Report Third Quarter 2022 Financial Results on November 7, 2022","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10591/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-10-21T11:00:20","lastUpdatedUTC":"2022-10-21T11:00:20"},{"id":10581,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10581","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-availability-auvelitytm-first-and"},"title":"Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults","type":{"title":"General","id":3886},"teaser":"AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared to placebo starting at one week 1-4 Auvelity On My Side offers comprehensive patient support services including access and prescription drug","language":"en","releaseDate":{"dateUTC":"2022-10-20T11:00:00","date":"2022-10-20T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10581/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-10-20T11:00:55","lastUpdatedUTC":"2022-10-20T11:00:55"},{"id":10576,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10576","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-voices-its-commitment-mental-health-world"},"title":"Axsome Therapeutics Voices its Commitment to Mental Health on World Mental Health Day 2022","type":{"title":"General","id":3886},"teaser":"NEW YORK , Oct. 10, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, is joining the World Health Organization’s ( WHO ) 2022 World Mental Health Day","language":"en","releaseDate":{"dateUTC":"2022-10-10T11:00:00","date":"2022-10-10T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Voices its Commitment to Mental Health on World Mental Health Day 2022","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10576/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-10-10T11:00:34","lastUpdatedUTC":"2022-10-10T11:00:34"},{"id":10566,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10566","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-sunosir-solriamfetol-meets-primary"},"title":"Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea","type":{"title":"General","id":3886},"teaser":"Statistically significant improvement in cognitive function, as measured by the DSST RBANS compared to placebo (p=0.009, primary endpoint) Statistically significant patient-reported improvement in cognitive function, as measured by the BC-CCI compared to placebo (p=0.002) Reduced excessive daytime","language":"en","releaseDate":{"dateUTC":"2022-10-03T10:30:00","date":"2022-10-03T06:30:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10566/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-10-03T10:30:34","lastUpdatedUTC":"2022-10-03T10:30:34"},{"id":10556,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10556","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-plans-resubmit-axs-07-nda-based"},"title":"Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting","type":{"title":"General","id":3886},"teaser":"NEW YORK , Sept. 29, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced that, following a Type A meeting with the U.S.","language":"en","releaseDate":{"dateUTC":"2022-09-29T11:28:00","date":"2022-09-29T07:28:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10556/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-09-29T11:28:10","lastUpdatedUTC":"2022-09-29T11:28:10"},{"id":10546,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10546","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-present-ladenburg-thalmann-healthcare"},"title":"Axsome Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference","type":{"title":"General","id":3886},"teaser":"NEW YORK , Sept. 21, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau , MD, Axsome’s Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2022-09-21T11:00:00","date":"2022-09-21T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10546/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-09-21T11:00:40","lastUpdatedUTC":"2022-09-21T11:00:40"},{"id":10536,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10536","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-present-cowen-2nd-annual-novel-mechanisms"},"title":"Axsome Therapeutics to Present at the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit","type":{"title":"General","id":3886},"teaser":"NEW YORK , Sept. 14, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau , MD, Axsome’s Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2022-09-14T11:00:00","date":"2022-09-14T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Present at the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10536/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-09-14T11:00:25","lastUpdatedUTC":"2022-09-14T11:00:25"},{"id":10521,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10521","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-initiates-advance-2-phase-3-trial-axs-05"},"title":"Axsome Therapeutics Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation","type":{"title":"General","id":3886},"teaser":"NEW YORK , Sept. 08, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced that it has enrolled the first patient in the ADVANCE-2 trial of","language":"en","releaseDate":{"dateUTC":"2022-09-08T11:00:00","date":"2022-09-08T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10521/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-09-08T11:00:34","lastUpdatedUTC":"2022-09-08T11:00:34"},{"id":10516,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10516","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-publication-post-hoc-analysis"},"title":"Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research","type":{"title":"General","id":3886},"teaser":"NEW YORK , Sept. 07, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the publication of a post-hoc analysis comparing the effects of","language":"en","releaseDate":{"dateUTC":"2022-09-07T11:00:00","date":"2022-09-07T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10516/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-09-07T11:00:36","lastUpdatedUTC":"2022-09-07T11:00:36"},{"id":10511,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10511","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-present-morgan-stanley-20th-annual-global"},"title":"Axsome Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference","type":{"title":"General","id":3886},"teaser":"NEW YORK , Sept. 06, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau , MD, Axsome’s Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2022-09-06T11:00:00","date":"2022-09-06T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10511/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-09-06T11:02:29","lastUpdatedUTC":"2022-09-06T11:02:29"},{"id":10501,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10501","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-initiates-emerge-phase-3-open-label-trial"},"title":"Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor","type":{"title":"General","id":3886},"teaser":"NEW YORK , Sept. 01, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced that it has enrolled the first patient in the EMERGE trial of AXS-07","language":"en","releaseDate":{"dateUTC":"2022-09-01T11:00:00","date":"2022-09-01T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10501/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-09-01T11:00:35","lastUpdatedUTC":"2022-09-01T11:00:35"},{"id":10466,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10466","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-fda-approval-auvelitytm-first-and"},"title":"Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults","type":{"title":"General","id":3886},"teaser":"AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared to placebo starting at one week 1 -4 AUVELITY uses the first new oral mechanism of action approved for major depressive disorder in over 60","language":"en","releaseDate":{"dateUTC":"2022-08-19T10:45:00","date":"2022-08-19T06:45:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10466/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-08-19T10:47:13","lastUpdatedUTC":"2022-08-19T10:47:13"},{"id":10451,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10451","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-reports-second-quarter-2022-financial"},"title":"Axsome Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update","type":{"title":"Earnings","id":3896},"teaser":"Company to host conference call today at 8:00 AM Eastern NEW YORK , Aug. 09, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today reported","language":"en","releaseDate":{"dateUTC":"2022-08-09T11:00:00","date":"2022-08-09T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10451/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-08-09T11:00:40","lastUpdatedUTC":"2022-08-09T11:00:40"},{"id":10441,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10441","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-report-second-quarter-2022-financial-results"},"title":"Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022","type":{"title":"General","id":3886},"teaser":"Axsome to host conference call and webcast on Tuesday, August 9, 2022 at 8:00 AM Eastern Time NEW YORK , July 28, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system","language":"en","releaseDate":{"dateUTC":"2022-07-28T11:00:00","date":"2022-07-28T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10441/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-07-28T11:00:41","lastUpdatedUTC":"2022-07-28T11:00:41"},{"id":10421,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10421","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-hosts-sunosir-investor-update-virtual-event"},"title":"Axsome Therapeutics Hosts Sunosi® Investor Update Virtual Event Today with Key Opinion Leaders","type":{"title":"General","id":3886},"teaser":"NEW YORK , June 28, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, is hosting a virtual event today at 9:00 AM EDT to provide investors an update","language":"en","releaseDate":{"dateUTC":"2022-06-28T11:00:00","date":"2022-06-28T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Hosts Sunosi® Investor Update Virtual Event Today with Key Opinion Leaders","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10421/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-06-28T11:00:38","lastUpdatedUTC":"2022-06-28T11:00:38"},{"id":10406,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10406","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-host-sunosir-investor-update-virtual-event"},"title":"Axsome Therapeutics to Host Sunosi® Investor Update Virtual Event","type":{"title":"General","id":3886},"teaser":"NEW YORK , June 22, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will host a virtual event on Tuesday, June 28, 2022 at","language":"en","releaseDate":{"dateUTC":"2022-06-22T11:00:00","date":"2022-06-22T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Host Sunosi® Investor Update Virtual Event","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10406/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-06-22T11:00:34","lastUpdatedUTC":"2022-06-22T11:00:34"},{"id":10376,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10376","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-results-support-survey-patients"},"title":"Axsome Therapeutics Announces Results of the SUPPORT Survey of Patients with Major Depressive Disorder Presented at the American Society of Clinical Psychopharmacology Association (ASCP) 2022 Annual Meeting","type":{"title":"Earnings","id":3896},"teaser":"Survey conducted in collaboration with the Depression and Bipolar Support Alliance (DBSA) Survey respondents reported persistence of high levels of depressive symptoms and interference with work and daily functioning despite treatment Respondents reported low levels of hope and high levels of","language":"en","releaseDate":{"dateUTC":"2022-06-06T11:00:00","date":"2022-06-06T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Announces Results of the SUPPORT Survey of Patients with Major Depressive Disorder Presented at the American Society of Clinical Psychopharmacology Association (ASCP) 2022 Annual Meeting","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10376/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-06-06T11:00:31","lastUpdatedUTC":"2022-06-06T11:00:31"},{"id":10366,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10366","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-presents-new-data-gemini-trial-demonstrating"},"title":"Axsome Therapeutics Presents New Data from the GEMINI Trial Demonstrating Efficacy of AXS-05 on Anhedonia in Patients with Major Depressive Disorder","type":{"title":"General","id":3886},"teaser":"AXS-05 rapidly and significantly improved anhedonic symptoms, measured by the MADRS anhedonia subscale, starting 1 week after treatment Data being presented at the American Society of Clinical Psychopharmacology (ASCP) 2022 Annual Meeting NEW YORK , June 02, 2022 (GLOBE NEWSWIRE) -- Axsome","language":"en","releaseDate":{"dateUTC":"2022-06-02T11:00:00","date":"2022-06-02T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Presents New Data from the GEMINI Trial Demonstrating Efficacy of AXS-05 on Anhedonia in Patients with Major Depressive Disorder","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10366/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-06-02T11:00:20","lastUpdatedUTC":"2022-06-02T11:00:20"},{"id":10356,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10356","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-late-breaking-presentations"},"title":"Axsome Therapeutics Announces Late-Breaking Presentations of Positive Results of the EVOLVE Trial of AXS-05 in Major Depressive Disorder After Prior Treatment Failures at the American Society of Clinical Psychopharmacology (ASCP) 2022 Annual Meeting","type":{"title":"Earnings","id":3896},"teaser":"Rapid, substantial, and durable improvement in depressive symptoms (MADRS), and functioning (SDS) with AXS-05, sustained over 12 months, (p","language":"en","releaseDate":{"dateUTC":"2022-06-01T11:00:00","date":"2022-06-01T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Announces Late-Breaking Presentations of Positive Results of the EVOLVE Trial of AXS-05 in Major Depressive Disorder After Prior Treatment Failures at the American Society of Clinical Psychopharmacology (ASCP) 2022 Annual Meeting","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10356/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-06-01T11:00:46","lastUpdatedUTC":"2022-06-01T11:00:46"},{"id":10346,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10346","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-publication-pivotal-gemini-phase-3"},"title":"Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry","type":{"title":"General","id":3886},"teaser":"AXS-05 (dextromethorphan-bupropion) demonstrated rapid, substantial, and statistically significant antidepressant efficacy compared to placebo starting 1 week after treatment NEW YORK , May 31, 2022 /PRNewswire/ -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and","language":"en","releaseDate":{"dateUTC":"2022-05-31T11:00:00","date":"2022-05-31T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10346/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-05-31T11:00:44","lastUpdatedUTC":"2022-05-31T11:00:44"},{"id":10336,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10336","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-publication-pivotal-ascend-phase-2"},"title":"Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of Psychiatry","type":{"title":"General","id":3886},"teaser":"In this study, AXS-05 (dextromethorphan-bupropion) demonstrated rapid, substantial, and statistically significant antidepressant efficacy compared with the active comparator bupropion NEW YORK , May 18, 2022 /PRNewswire/ -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company","language":"en","releaseDate":{"dateUTC":"2022-05-18T11:00:00","date":"2022-05-18T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of Psychiatry","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10336/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-05-18T11:01:10","lastUpdatedUTC":"2022-05-18T12:40:44"},{"id":10326,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10326","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-supports-national-alliance-mental-illness"},"title":"Axsome Therapeutics Supports the National Alliance on Mental Illness (NAMI) to Recognize Mental Health Awareness Month","type":{"title":"General","id":3886},"teaser":"NEW YORK , May 16, 2022 /PRNewswire/ – Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, is supporting the National Alliance on Mental Illness (NAMI) during Mental Health","language":"en","releaseDate":{"dateUTC":"2022-05-16T11:00:00","date":"2022-05-16T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Supports the National Alliance on Mental Illness (NAMI) to Recognize Mental Health Awareness Month","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10326/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-05-16T11:01:01","lastUpdatedUTC":"2022-05-16T15:44:12"},{"id":10321,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10321","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-completes-us-acquisition-sunosir-0"},"title":"Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea","type":{"title":"General","id":3886},"teaser":"Axsome is committed to providing patients uninterrupted access to Sunosi and advancing research for patients living with sleep disorders Insurance coverage for Sunosi totals 96% of commercial lives or approximately 253 million lives across all channels Comprehensive patient assistance program for","language":"en","releaseDate":{"dateUTC":"2022-05-09T11:00:00","date":"2022-05-09T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10321/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-05-09T11:49:00","lastUpdatedUTC":"2022-05-16T16:23:33"},{"id":10286,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10286","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-reports-first-quarter-2022-financial-results"},"title":"Axsome Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update","type":{"title":"Earnings","id":3896},"teaser":"Company to host conference call today at 8:00 AM Eastern NEW YORK , May 2, 2022 /PRNewswire/ -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the","language":"en","releaseDate":{"dateUTC":"2022-05-02T11:05:00","date":"2022-05-02T07:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10286/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-05-02T11:05:19","lastUpdatedUTC":"2022-05-16T16:21:11"},{"id":10281,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10281","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-receives-fda-complete-response-letter-new"},"title":"Axsome Therapeutics Receives FDA Complete Response Letter for New Drug Application for AXS-07 for the Acute Treatment of Migraine","type":{"title":"General","id":3886},"teaser":"No clinical efficacy or safety issues raised and no additional clinical studies required by FDA to support approval Company plans to engage with FDA toward expeditious resolution of outstanding items NEW YORK , May 2, 2022 /PRNewswire/ -- Axsome Therapeutics, Inc.","language":"en","releaseDate":{"dateUTC":"2022-05-02T11:00:00","date":"2022-05-02T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Receives FDA Complete Response Letter for New Drug Application for AXS-07 for the Acute Treatment of Migraine","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10281/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-05-02T11:00:51","lastUpdatedUTC":"2022-05-16T16:21:51"},{"id":10266,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10266","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-report-first-quarter-2022-financial-results"},"title":"Axsome Therapeutics to Report First Quarter 2022 Financial Results on May 2, 2022","type":{"title":"General","id":3886},"teaser":"Axsome to host conference call and webcast on Monday, May 2, 2022 at 8:00 AM Eastern Time NEW YORK , April 25, 2022 /PRNewswire/ -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today","language":"en","releaseDate":{"dateUTC":"2022-04-25T11:00:00","date":"2022-04-25T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Report First Quarter 2022 Financial Results on May 2, 2022","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10266/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-04-25T11:00:54","lastUpdatedUTC":"2022-05-16T16:22:29"},{"id":10236,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10236","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-acquire-sunosir-jazz-pharmaceuticals"},"title":"Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome’s Leadership in Neuroscience","type":{"title":"General","id":3886},"teaser":"Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) approved by the FDA to improve wakefulness in adults living with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea Acquisition accelerates Axsome’s transformation into a","language":"en","releaseDate":{"dateUTC":"2022-03-28T10:00:00","date":"2022-03-28T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome’s Leadership in Neuroscience","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10236/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-03-28T10:01:33","lastUpdatedUTC":"2022-05-16T16:25:11"},{"id":10216,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10216","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-participate-1st-annual-needham-virtual"},"title":"Axsome Therapeutics to Participate in the 1st Annual Needham Virtual Neuroscience Forum","type":{"title":"General","id":3886},"teaser":"NEW YORK , March 11, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau , MD, Axsome’s Chief Executive Officer, will participate","language":"en","releaseDate":{"dateUTC":"2022-03-11T12:00:00","date":"2022-03-11T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Participate in the 1st Annual Needham Virtual Neuroscience Forum","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10216/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-03-11T12:01:09","lastUpdatedUTC":"2022-05-16T16:26:15"},{"id":10176,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10176","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-present-cowen-42nd-annual-health-care"},"title":"Axsome Therapeutics to Present at the Cowen 42nd Annual Health Care Conference","type":{"title":"General","id":3886},"teaser":"NEW YORK , March 02, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau , MD, Axsome’s Chief Executive Officer, will participate","language":"en","releaseDate":{"dateUTC":"2022-03-02T12:00:00","date":"2022-03-02T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Present at the Cowen 42nd Annual Health Care Conference","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10176/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-03-02T12:03:04","lastUpdatedUTC":"2022-03-02T12:03:04"},{"id":10151,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10151","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-reports-fourth-quarter-and-full-year-2021"},"title":"Axsome Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update","type":{"title":"Earnings","id":3896},"teaser":"Company to host conference call today at 8:00 AM Eastern NEW YORK , March 01, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for","language":"en","releaseDate":{"dateUTC":"2022-03-01T12:00:00","date":"2022-03-01T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10151/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-03-01T12:05:53","lastUpdatedUTC":"2022-03-01T12:05:53"},{"id":10146,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10146","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-report-fourth-quarter-and-full-year-2021"},"title":"Axsome Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022","type":{"title":"General","id":3886},"teaser":"Axsome to host conference call and webcast on Tuesday, March 1, 2022 at 8:00 AM Eastern Time NEW YORK , Feb. 15, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders,","language":"en","releaseDate":{"dateUTC":"2022-02-15T12:00:00","date":"2022-02-15T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10146/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-02-15T12:00:57","lastUpdatedUTC":"2022-02-15T12:00:57"},{"id":10136,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10136","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-present-11th-annual-svb-leerink-global"},"title":"Axsome Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference","type":{"title":"General","id":3886},"teaser":"NEW YORK , Feb. 11, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau , MD, Axsome’s Chief Executive Officer, will participate","language":"en","releaseDate":{"dateUTC":"2022-02-11T12:00:00","date":"2022-02-11T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10136/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-02-11T12:01:58","lastUpdatedUTC":"2022-02-11T12:01:58"},{"id":10051,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10051","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-reports-third-quarter-2021-financial-results"},"title":"Axsome Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update","type":{"title":"Earnings","id":3896},"teaser":"Company to host conference call today at 8:00 AM Eastern NEW YORK , Nov. 08, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for","language":"en","releaseDate":{"dateUTC":"2021-11-08T12:00:00","date":"2021-11-08T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10051/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-11-08T12:01:55","lastUpdatedUTC":"2021-11-08T12:01:55"},{"id":10041,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10041","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-report-third-quarter-2021-financial-results"},"title":"Axsome Therapeutics to Report Third Quarter 2021 Financial Results on November 8, 2021","type":{"title":"General","id":3886},"teaser":"Axsome to host conference call and webcast on Monday, November 8, 2021 at 8:00 AM Eastern Time NEW YORK , Oct. 20, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders,","language":"en","releaseDate":{"dateUTC":"2021-10-20T11:00:00","date":"2021-10-20T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics to Report Third Quarter 2021 Financial Results on November 8, 2021","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10041/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-10-20T11:02:17","lastUpdatedUTC":"2021-10-20T11:02:17"},{"id":10031,"link":{"url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10031","hostedUrl":"http://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-expands-term-loan-facility-hercules-capital"},"title":"Axsome Therapeutics Expands Term Loan Facility with Hercules Capital to $300 Million","type":{"title":"General","id":3886},"teaser":"$100 million now available upon the potential FDA approval of AXS-05 NEW YORK , Oct. 18, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that its","language":"en","releaseDate":{"dateUTC":"2021-10-18T11:00:00","date":"2021-10-18T07:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Axsome Therapeutics Expands Term Loan Facility with Hercules Capital to $300 Million","url":"https://clientapi.gcs-web.com/data/a2772e48-203c-4d1a-9d97-ddd0c8b88945/news/10031/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-10-18T11:01:00","lastUpdatedUTC":"2021-10-18T11:01:00"}],"error":null}